Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 377
116th Congress(2019-2020)
Medicare Negotiation and Competitive Licensing Act of 2019
Introduced
Introduced
Introduced in Senate on Feb 7, 2019
Overview
Text
Introduced
Feb 7, 2019
Latest Action
Feb 7, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
377
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Sherrod Brown
Ohio
Democrat
Kamala Harris
California
Democrat
Elizabeth Warren
Massachusetts
Democrat
Amy Klobuchar
Minnesota
Democrat
Tammy Baldwin
Wisconsin
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Medicare Negotiation and Competitive Licensing Act of 2019

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)

The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.

Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

Text (1)
Introduced in Senate
February 7, 2019
Related Bills (1)
Feb 07, 2019
Introduced in House
128
Sponsorship
House Bill 1046
Medicare Negotiation and Competitive Licensing Act of 2019
Introduced
Type
Related Bill
Related Bill
A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-Congress measures.
Identified By
CRS
Actions (2)
02/07/2019
Read twice and referred to the Committee on Finance.
02/07/2019
Introduced in Senate
Public Record
Record Updated
Nov 1, 2022 3:47:46 PM
Copyright © 2024 Civic Bits LLC
Privacy Policy
Terms of Service
What's New
About